Aura Biosciences, Inc.
AURANasdaqHealthcare · Biological Products, (No Diagnostic Substances) · DE · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — |
| Operating income | −$112.8M | −$96.1M | −$85.0M | −$60.3M | −$35.3M | −$22.2M |
| Net income | −$106.2M | −$86.9M | −$76.4M | −$58.8M | −$35.3M | −$22.2M |
| Total assets | $169.4M | $182.5M | $255.1M | $223.9M | $160.0M | $22.1M |
| Total liabilities | $32.5M | $30.5M | $29.2M | $28.4M | $7.7M | $2.7M |
| Equity | $136.9M | $152.0M | $225.8M | $195.6M | $152.3M | −$108.7M |
| EPS (diluted) | $-1.76 | $-1.75 | $-1.93 | $-1.96 | $-8.95 | — |
| Shares out. | 50.2M | 49.5M | 37.8M | 29.2M | 29.2M | 381,123 |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- —
- Net margin
- —
- Return on equity
- −77.6%
- Return on assets
- −62.7%
- Return on capital (ROCE)
- −74.7%
- Liabilities / assets
- 19.2%
- Debt / equity
- 0.24×
- Book value / share
- $2.73
- Revenue growth (YoY)
- —
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Altman Z″ (distress)
- -4.21distress
- Accruals / assets
- −12.7%clean
- Piotroski F-Score
- 1/7weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast. What these scores mean →
Signs
● 1 severe● 1 warning● 2 good- Altman Z″ in the distress zone
- Negative operating cash flow
- Conservative leverage (liabilities < 50% of assets)
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Clinical trials
ClinicalTrials.gov · ongoing · next readout first- Phase 2Recruitingreadout ~2026-11-30Suprachoroidal Administration in Subjects With Metastases to the Choroid
- Phase 1Recruitingreadout ~2027-03A Phase 1, Open-label Trial of Belzupacap Sarotalocan (AU-011) in Bladder Cancer
- Phase 3Recruitingreadout ~2027-11-15A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects With Primary Indeterminate Lesions or Small Choroidal Melanoma
Interventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- Tcg Crossover Gp Ii, LlcPassive (13G)May 12, 2026
- Matrix Capital Management Company, LpActivist (13D)May 11, 2026
- Advent Life Sciences LlpPassive (13G)Feb 17, 2026
- Frazier Life Sciences Public Fund, L.P.Passive (13G)Feb 13, 2026
- Blackrock, Inc.Passive (13G)Oct 17, 2025
- Suvretta Capital Management, LlcPassive (13G)Aug 13, 2025
- Long Focus Capital Management, LlcPassive (13G)May 15, 2025
- Eventide Asset Management, LlcPassive (13G)May 14, 2025
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Holles Natalie C.Officer — See Remarks | May 19, 2026 | Grant | 600,118 | $0.00 |
| Matrix Capital Management Company, Lp10% owner | May 7, 2026 | Sell | 6.9M | $5.64 |
| Kilroy ConorOfficer — See Remarks | Apr 16, 2026 | Sell | 11,738 | $7.02 |
| Kilroy ConorOfficer — See Remarks | Mar 2, 2026 | Grant | 62,339 | $0.00 |
| Gibney Anthony SOfficer — See Remarks | Mar 2, 2026 | Grant | 71,245 | $0.00 |
| De Los Pinos ElisabetOfficer — See Remarks | Mar 2, 2026 | Grant | 166,000 | $0.00 |
| Plavsic MarkOfficer — Chief Technology Officer | Mar 2, 2026 | Grant | 62,339 | $0.00 |
| Hopkins Janet JillOfficer — Chief Medical Officer | Mar 2, 2026 | Grant | 89,056 | $0.00 |
| Elazzouzi AmyOfficer — Senior Vice President, Finance | Mar 2, 2026 | Grant | 44,528 | $0.00 |
| Kilroy ConorOfficer — See Remarks | Feb 17, 2026 | Sell | 12,079 | $5.05 |
| Plavsic MarkOfficer — Chief Technology Officer | Feb 17, 2026 | Sell | 15,890 | $5.05 |
| Hopkins Janet JillOfficer — Chief Medical Officer | Feb 17, 2026 | Sell | 20,401 | $5.06 |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 3.2M | 2.8 | +44.0% |
| Apr 30, 2026 | 2.2M | 8.0 | +8.9% |
| Apr 15, 2026 | 2.0M | 6.1 | -23.0% |
| Mar 31, 2026 | 2.6M | 8.9 | +4.3% |
| Mar 13, 2026 | 2.5M | 8.9 | +11.5% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Results of operations · Other material eventMay 11, 2026
- Entered a material agreementMay 5, 2026
- Entered a material agreement · Results of operations · Other material eventMay 4, 2026
- Director / officer change · Regulation FD disclosure · Other material eventMay 4, 2026
- Results of operations · Other material eventMar 30, 2026
- Results of operations · Other material eventNov 13, 2025
- Results of operations · Other material eventAug 13, 2025
- Shareholder voteJun 18, 2025
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗- 4May 19, 2026
- S-8May 19, 2026
- SCHEDULE 13GMay 12, 2026
- 4OWNERSHIP DOCUMENTMay 11, 2026
- 10-QMay 11, 2026
- SCHEDULE 13D/AMay 11, 2026
- 8-KMay 11, 2026
- 3May 7, 2026
- 8-KMay 5, 2026
- 424B5May 5, 2026
- 8-KMay 4, 2026
- DEFA14AMay 4, 2026
- S-3MEFMay 4, 2026
- 424B5May 4, 2026
- 8-KMay 4, 2026
Event-driven situations (2)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.